Visikol leverages the HUREL micro liver models to provide its clients with a suite of best-in-class liver in vitro assays.
Multi-Parameter Toxicity
Our Multi-Parameter Toxicity assay’s apply HUREL’s superior metabolic competency to a panel of complementary assays, creating a multi-parametric characterization of hepatotoxic risk. HUREL Tox™ incorporates a 14-day, repeat-dose cytotoxicity study with both ATP and albumin (ELISA) readouts.
Our cytotoxicity and hepatotoxicity screening service makes early, high-acuity assessment of hepatotoxic risk cost-effective for smaller organizations and thereby brings new illumination to the challenge of reducing late-stage candidate attrition.
The HUREL micro liver coculture system is a robust and reliable method for human in vivo clearance prediction and metabolite detection of slowly metabolized drugs.
The HUREL Viral™ platform aids the study of viral persistence and accelerates the development of antiviral drugs not just to mitigate recurring symptoms of but to fully cure chronic hepatitis B (HBV).
Hepatobiliary research services based on a new, patent-pending efflux transporter assay method. Visikol’s HUREL primary hepatocyte co-cultures allow the hepatocytes to polarize and form stable and enduring biliary canaliculi networks and their associated transporters for over 30 days.
